Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer
Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).
- Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).
- View the full release here: https://www.businesswire.com/news/home/20231115733368/en/
Erik van den Berg, CEO of Memo Therapeutics AG (Photo: Business Wire)
Mr. van den Berg joins MTx with over 25 years’ industry experience and proven track record in leading and growing companies. - Previously, Mr. van den Berg also held business development roles at Organon and IsoTis (sold to Integra Lifesciences).
- Mr. van den Berg holds a master’s degree in chemistry from the University of Utrecht and an MBA from Manchester Business School.